ABBOTT LABORATORIES Prices Notes Offering for $20.00B

The eight tranches, their principal amounts, coupons and maturities are: Floating Rate Notes due 2029 ($1.0 billion, SOFR plus 0.500%, maturing March 9, 2029); 3.700% Notes due 2029 ($2.25 billion, maturing March 9, 2029); 4.000% Notes due 2031 ($2.5 billion, maturing March 15, 2031); 4.300% Notes due 2033 ($2.75 billion, maturing March 15, 2033); 4.650% Notes due 2036 ($3.75 billion, maturing March 15, 2036); 4.750% Notes due 2038 ($2.0 billion, maturing March 15, 2038); 5.500% Notes due 2056 ($3.75 billion, maturing March 15, 2056); and 5.600% Notes due 2066 ($2.0 billion, maturing March 15, 2066). Settlement for all tranches occurred March 9, 2026.

Per the final pricing term sheet (free writing prospectus filed February 24, 2026), the fixed-rate tranches priced at the following prices to public and yields to maturity: the 2029 Notes at 99.873% (yield 3.745%, +30 bps to the benchmark 3.500% Treasury due February 15, 2029); the 2031 Notes at 99.855% (yield 4.032%, +45 bps to the 3.750% Treasury due January 31, 2031); the 2033 Notes at 99.813% (yield 4.331%, +55 bps to the 4.000% Treasury due January 31, 2033); the 2036 Notes at 99.753% (yield 4.681%, +65 bps to the 4.125% Treasury due February 15, 2036); the 2038 Notes at 99.718% (yield 4.781%, +75 bps to the same 2036 benchmark Treasury); the 2056 Notes at 99.882% (yield 5.508%, +80 bps to the 4.625% Treasury due November 15, 2055); and the 2066 Notes at 99.872% (yield 5.608%, +90 bps to the same 2055 benchmark Treasury). The Floating Rate Notes priced at 100.000% of par. Each fixed-rate tranche carries a par call date ranging from one to six months before its stated maturity, after which Abbott may redeem at par plus accrued interest; prior to the par call date, Abbott may redeem at a make-whole price based on the applicable Treasury rate plus a spread of 5 to 15 basis points depending on the tranche. The Floating Rate Notes are not redeemable prior to maturity except via special mandatory redemption.

Abbott estimated net proceeds of approximately $19,825,943,100 after underwriting discounts and estimated offering expenses, according to the prospectus supplement. Per-tranche underwriting discounts ranged from 0.250% (Floating Rate Notes and 2029 Notes) up to 0.875% (2056 and 2066 Notes). Abbott stated it intends to use the net proceeds, together with cash on hand and/or additional borrowings (which may include commercial paper issuances), to fund the cash consideration for its acquisition of Exact Sciences Corporation under an Agreement and Plan of Merger dated November 19, 2025 (Abbott, Exact Sciences and Badger Merger Sub I, Inc.), to repay certain existing indebtedness of Exact Sciences, to pay related fees and expenses, and for general corporate purposes, which may include repayment of other indebtedness. The notes are unsecured, unsubordinated obligations ranking equally with Abbott's other unsecured and unsubordinated debt.

The notes carry a special mandatory redemption feature: if the Exact Sciences acquisition is not consummated within five business days after the later of February 17, 2027 or any later merger-agreement "End Date," or if Abbott notifies the trustee it will not pursue the acquisition, Abbott must redeem all outstanding notes at 101% of principal plus accrued and unpaid interest to the special mandatory redemption date.

The joint book-running managers across all eight tranches were Morgan Stanley, Barclays, BofA Securities and J.P. Morgan. Additional joint book-running managers with tranche-specific roles were BNP Paribas (2031 and 2038 Notes), Citigroup (Floating Rate Notes, 2029 Notes and 2066 Notes), Deutsche Bank Securities (2056 Notes), MUFG (2033 Notes) and Societe Generale (2036 Notes). The senior co-manager tier included Santander, HSBC, RBC Capital Markets, Siebert Williams Shank, BBVA, Mizuho, Academy Securities, U.S. Bancorp, Goldman Sachs, Standard Chartered Bank and ING, generally covering all or multiple tranches. The notes were issued under an existing indenture dated March 10, 2015 between Abbott and U.S. Bank National Association, as supplemented by an officers' certificate dated March 9, 2026.

For legal counsel, the prospectus supplement states that certain legal matters in connection with the offering were passed upon for Abbott by Wachtell, Lipton, Rosen & Katz, New York, and for the underwriters by Davis Polk & Wardwell LLP, New York.

No credit rating agency names (Moody's, S&P or Fitch) or specific assigned ratings appear in the prospectus supplement, the pricing term sheet, or either Form 8-K reviewed. As disclosed, the notes are not listed on any national securities exchange and there is currently no public trading market for them.